Aytu biopharma expects positive cash flow with the growth of hyperactivity disorder, lack of attention and provision annually at a value of $ 2 million

Aytu biopharma expects positive cash flow with the growth of hyperactivity disorder, lack of attention and provision annually at a value of $ 2 million



[og_img]

Source link